Myriad Genetics Inc. (Nasdaq: MYGN) reported sharply higher fourth quarter earnings of 37 cents per share compared with 23 cents per share a year earlier prompting an upgrade. Shares of the molecular diagnostic products company leaped $4.45 to $30.33.
